Emerging data suggest Retatrutide , a dual activator targeting both the gut-brain axis and glucose-dependent insulinotropic polypeptide , could offer a significant step forward for obesity treatment. Preliminary human investigations have demonstrated considerable decreases in abdominal mass , possibly surpassing existing obesity therapies . Neverth